Vera Therapeutics (VERA) AI Stock Analysis

• Market Cap: $2.99B
• Dividend Yield: N/A
• Average Volume (3M): 1.47M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.41
• Revenue Growth: N/A
• EPS Growth: -53.44%
• Country: US
• Employees: 152
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.26
• Shares Outstanding: 70,066,180
• 10 Day Avg. Volume: 1,120,971
• 30 Day Avg. Volume: 1,474,393
• PEG Ratio: -0.69
• Price to Book (P/B): 4.05
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -17.25
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -2.56K
• Enterprise Value/Ebitda: -11.88
• 1Y Price Target: $69.30
• Price Target Upside: 62.14% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 56 Neutral
• Price Target: $46.00 ▲(7.63% Upside)

The score is held back primarily by weak financial performance (no revenue, widening losses, and heavy cash burn), despite a supportive balance sheet. Technicals are a clear positive with strong trend and momentum, while valuation remains challenged due to ongoing losses and no dividend. Recent corporate events add a constructive tailwind via Phase 3 results and fresh capital, tempered by executive turnover.

Positive Factors

Phase 3 clinical efficacy

Robust Phase 3 efficacy and clean safety materially de-risk atacicept's path to approval for IgA nephropathy, improving the realistic chance of commercialization and long-term revenue potential; this strengthens strategic positioning vs competitors in a focused kidney-disease franchise.

Substantial fresh capital

A large, recent equity raise extends runway, reduces immediate financing pressure and funds late-stage development and regulatory activities; this durable liquidity buffer supports execution of pivotal commercialization steps and reduces near-term dilution risk from emergency financings.

Moderate leverage and stronger equity base

Low debt levels and a growing equity base mean the company is not highly leveraged, preserving financial flexibility to fund R&D and absorb losses. This capitalization profile supports sustained clinical programs and potential partnering or licensing negotiations without heavy interest burden.

Negative Factors

Pre-revenue with widening losses

The company remains without product revenue while losses have escalated sharply, meaning long-term viability depends on successful approval/commercialization or repeated external funding. Persistent negative profitability raises dilution and execution risk if clinical or regulatory timelines slip.

Accelerating cash burn

Rapidly increasing operating cash outflows create a structural dependence on capital markets; even with recent proceeds, sustained negative free cash flow can force future financings on potentially dilutive terms, constraining strategic options and pace of commercial rollout.

Senior legal leadership turnover

Loss of a key legal executive during late-stage development and regulatory engagement may slow filings, partnering negotiations or compliance oversight. Leadership gaps in legal/governance can create execution risk during crucial approval and commercial-prep periods if not promptly replaced.

Vera Therapeutics Business Overview & Revenue Model

Company Description

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

How the Company Makes Money

Vera Therapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. The company's revenue model includes licensing agreements, research collaborations, and eventually, sales of approved therapies. Key revenue streams involve upfront payments, milestone payments, and royalties from commercial partnerships with larger pharmaceutical companies. Significant partnerships with industry leaders and research organizations play a crucial role in advancing their drug development programs and contributing to potential future earnings.

Vera Therapeutics Financial Statement Overview

Summary

Clinical-stage profile with no revenue and materially widening losses alongside accelerating cash burn. Balance sheet leverage is moderate with meaningful equity, but ongoing negative profitability and large operating/free-cash-flow deficits imply continued reliance on external funding.

Income Statement

The company remains pre-revenue (zero revenue in annual periods and TTM (Trailing-Twelve-Months)), with losses widening materially over time. Net loss deteriorated from about $33M (2021) to ~$152M (2024) and ~$252M in TTM (Trailing-Twelve-Months), reflecting a sharp step-up in operating expense as the business scales R&D. While this is not unusual for a clinical-stage biotech, the absence of revenue and expanding losses keep earnings quality and profitability weak.

Balance Sheet

Leverage is moderate, with debt-to-equity at ~0.10 in 2024 and ~0.17 in TTM (Trailing-Twelve-Months), suggesting the company is not heavily debt-funded. Equity increased significantly versus 2022–2023, supporting a stronger capitalization profile, though returns remain deeply negative given ongoing losses (negative return on equity across recent years). The key weakness is that continued losses can pressure equity over time if funding markets tighten.

Cash Flow

Cash burn is substantial and accelerating: operating cash flow was about -$24M (2021), -$135M (2024), and roughly -$210M in TTM (Trailing-Twelve-Months), with free cash flow similarly negative. While free cash flow broadly tracks net losses (free cash flow to net income around ~1.0–1.14), indicating losses are largely cash-backed rather than accounting-driven, the scale of ongoing burn implies continued dependence on external financing. Recent free cash flow growth in TTM (Trailing-Twelve-Months) is slightly positive, but still deeply negative in absolute terms.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-1.13M	0.00	0.00	846.00K	0.00	-251.00K
EBITDA	-243.18M	-144.42M	-92.18M	-88.91M	-32.41M	-52.99M
Net Income	-251.94M	-152.15M	-95.99M	-89.06M	-32.61M	-53.41M
Balance Sheet
Total Assets	517.50M	655.68M	175.55M	131.44M	83.75M	54.55M
Cash, Cash Equivalents and Short-Term Investments	497.39M	640.85M	160.72M	114.65M	79.67M	53.65M
Total Debt	77.22M	54.64M	53.71M	31.29M	4.92M	2.00K
Total Liabilities	118.62M	78.53M	73.86M	54.53M	14.16M	143.90M
Stockholders Equity	398.88M	577.15M	101.69M	76.91M	69.59M	-89.35M
Cash Flow
Free Cash Flow	-211.47M	-135.65M	-92.24M	-67.66M	-23.71M	-34.91M
Operating Cash Flow	-210.29M	-134.68M	-92.18M	-67.60M	-23.71M	-34.81M
Investing Cash Flow	-107.76M	-425.03M	-39.43M	-70.55M	-4.20M	-42.00K
Financing Cash Flow	348.57M	606.67M	133.54M	101.93M	53.88M	85.29M

Vera Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 42.74
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VERA, the sentiment is Neutral. The current price of 42.74 is below the 20-day moving average (MA) of 46.05, below the 50-day MA of 45.65, and above the 200-day MA of 29.79, indicating a neutral trend. The MACD of -0.86 indicates Positive momentum. The RSI at 37.29 is Neutral, neither overbought nor oversold. The STOCH value of 14.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VERA.

Vera Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VRDN	60 Neutral	$2.90B	-8.59	-47.40%	―	23340.07%	18.06%
VERA	56 Neutral	$2.99B	-10.72	-73.25%	―	―	-53.44%
PHVS	56 Neutral	$1.70B	-8.25	-51.81%	―	―	-20.08%
EWTX	55 Neutral	$3.01B	-18.05	-30.02%	―	―	-5.73%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JANX	49 Neutral	$801.77M	-7.96	-12.48%	―	-23.37%	-42.45%
BHVN	48 Neutral	$1.60B	-1.45	-522.08%	―	―	18.76%

Vera Therapeutics Corporate Events

Vera Therapeutics Announces Departure of Chief Legal Officer

On December 16, 2025, Vera Therapeutics, Inc. announced that Jason Carter will step down from his role as Chief Legal Officer, effective December 24, 2025. The leadership change removes a key executive from the company’s legal function and may signal an upcoming transition or reorganization within its senior management team.

The most recent analyst rating on (VERA) stock is a Buy with a $97.00 price target. To see the full list of analyst forecasts on Vera Therapeutics stock, see the VERA Stock Forecast page.

Vera Therapeutics Completes Successful Stock Offering

On December 9, 2025, Vera Therapeutics, Inc. announced a follow-on public offering of 6,138,108 shares of its Class A common stock at a price of $42.50 per share, expected to generate approximately $260.9 million in gross proceeds. The offering, set to close on December 11, 2025, includes an option for underwriters to purchase an additional 920,716 shares, which was fully exercised on December 10, 2025. This move is part of Vera Therapeutics’ strategy to strengthen its financial position and potentially expand its market presence, with implications for stakeholders depending on market conditions and other external factors.

The most recent analyst rating on (VERA) stock is a Buy with a $97.00 price target. To see the full list of analyst forecasts on Vera Therapeutics stock, see the VERA Stock Forecast page.

Vera Therapeutics Appoints James R. Meyers to Board

On November 25, 2025, Vera Therapeutics, Inc. appointed James R. Meyers to its board as a Class II Director, with his term expiring at the 2026 Annual Meeting of Stockholders. Meyers will also serve on the Audit Committee and has been granted a stock option to purchase 25,000 shares, with additional compensation including a pro-rated annual cash retainer for 2025. This appointment is part of Vera Therapeutics’ strategy to strengthen its board with experienced leadership, potentially impacting its governance and operational oversight positively.

The most recent analyst rating on (VERA) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Vera Therapeutics stock, see the VERA Stock Forecast page.

Vera Therapeutics Announces Promising Phase 3 Trial Results

On November 6, 2025, Vera Therapeutics announced significant results from its ORIGIN Phase 3 trial of atacicept for IgA nephropathy, presented at the American Society of Nephrology Kidney Week and published in The New England Journal of Medicine. The trial showed a 46% reduction in proteinuria and favorable safety outcomes, positioning atacicept as a promising treatment option and potentially impacting the company’s market position positively.

The most recent analyst rating on (VERA) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Vera Therapeutics stock, see the VERA Stock Forecast page.